The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

Semaglutide, the GLP-1 drug that Novo sells under the brand names Ozempic for diabetes and Wegovy for weight loss, has made ...

Novo Nordisk's involve the GLP-1 pathway, while Eli Lilly's treatments activate both GLP-1 and GIP, known as dual GLP-1/GIP ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

Powers Health surgical and medical weight-loss services in Hobart and Munster provide tailored support and experts who ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The analysis used health data from the Rochester Epidemiology Project collected from 2000 to 2022. The first GLP-1 medication was prescribed beginning in 2006, and the authors included cases beginning ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Drugs that belong to the class of GLP-1 receptor agonists could cause muscle loss These drugs reduce appetite and are used ...

(Reuters) - U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for ...

SGLT2 diabetes meds like Jardiance or Farxiga do the same, and also decrease risk of a follow-up stroke Originally published ...